Primary Malignant Cardiac Tumors (PMCTs) Successful Resection of a Huge Liposarcoma of the Heart

Primary cardiac tumors are rare with an incidence ranging from 0.001% to 0.03% in autopsy series. The prognosis of cardiac sarcomas remains poor because it proliferates rapidly, and distant metastases are often found at diagnosis. We present a case of liposarcoma in the atrium of the heart as case report and same time ,we do a literature review about it.  Case Report: We present the case of a young 30 years old female with a significant tumor of cardiac liposarcoma, with chief complaint of dyspnea, tachycardia and heart failure even angina pectoris. Conclusion: The diagnostician’s differential diagnosis must be broad when encountering common chief complaints, such as tachycardia, heart failure and angina pectoris

Traumatic Pulmonary Pneumatoceles (Pseudocyst)

Introduction: Traumatic pulmonary parenchymal cavitary lesions (TPPCs) are pulmonary pseudocysts raiding secondary to lung contusion. Method: To provide an overview of the etiology, presentation, diagnosis and treatment of TPPCs, and to discuss this in the context of a cohort of 12 retrospectively reviewed patients with TPPCs presenting to Sahlgrenska University Hospital, Gothenburg, Sweden, from January 2014 to December 2016. Between January 2014 and December 2016, a total of twelve trauma patients presented to Sahlgrenska University Hospital with TPPC following blunt trauma. Results: TPPCs are of limited clinical consequence. Inexperienced clinicians may treat these inappropriately. A Computed Tomography (CT) scan is the investigation of choice. Treatment is symptomatic. Intervention is indicated only in case of complications

Use of medication for cardiovascular disease during pregnancy

One-third of women with heart disease use medication for the treatment of cardiovascular disease (CVD) during pregnancy. Increased plasma volume, renal clearance, and liver enzyme activity in pregnant women change the pharmacokinetics of these drugs, often resulting in the need for an increased dose. Fetal well-being is a major concern among pregnant women. Fortunately, many drugs used to treat CVD can be used safely during pregnancy, with the exception of high-dose warfarin in the first trimester, angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, amiodarone, and spironolactone. A timely and thorough discussion between the cardiologist and the pregnant patient about the potential benefits and adverse effects of medication for CVD is important. Noncompliance with necessary treatment for cardiovascular disorders endangers not only the mother, but also the fetus. This Review is an overview of the pharmacokinetic changes in medications for CVD during pregnancy and the safety of these drugs for the fetus. The implications for maternal treatment are discussed. The Review also includes a short section on the cardiovascular effects of medication used for obstetric indications